Around 70 cases of the Delta Plus variant were found by INSACOG (Indian SARS-CoV-2 Genomics Consortium), a group of 28 laboratories involved in genome sequencing, says Jitendra Singh, Union Science and Technology Minister in Parliament last week (in July).
‘Covaxin proves effective against the Delta Plus variant of COVID-19 as per an ICMR study. The vaccine demonstrated overall efficacy of 77.8% against symptomatic infection in July and now awaits WHO approval for emergency use listing (EUL).
’
Efficacy of Covaxin
Covaxin is the first indigenous vaccine of India to fight COVID-19, developed by Bharat Biotech, in collaboration with ICMR. So far, 430 million doses of vaccine have been distributed across India – one of the world’s largest vaccination drives.
The first interim analysis by Bharat Biotech – the Hyderabad-based company, revealed almost 81% efficacy for Covaxin in March. The analysis included 43 cases, of which 36 cases of COVID-19 were observed in the placebo group versus 7 cases observed in the BBV152 (Covaxin) group.
The second interim analysis released April showed that the vaccine’s efficacy against severe COVID-19 disease was 100%.
The vaccine demonstrated overall efficacy of 77.8% against symptomatic infection in July. The Company now affirms that it is in discussions with the World Health Organization (WHO) to obtain emergency use listing (EUL) for Covaxin.
Source: Medindia
Stay connected with us on social media platform for instant update click here to join our Twitter, & Facebook
We are now on Telegram. Click here to join our channel (@TechiUpdate) and stay updated with the latest Technology headlines.
For all the latest Health News Click Here
For the latest news and updates, follow us on Google News.
Denial of responsibility! NewsAzi is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.
